SITC Cancer Immunotherapy Guideline – Head and Neck

SITC Cancer Immunotherapy Guidelines (CIG) are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies.

Current Guideline

view guideline

SITC Cancer Immunotherapy Guidelines Head and Neck Subcommittee

CHAIR Robert L. Ferris, MD, PhD UPMC Hillman Cancer Center

CHAIR Ezra Cohen, MD University of California San Diego

Members

R. Bryan Bell, MD, DDS, FACS — Earle A. Chiles Research Institute, Providence Cancer Institute

Barbara A. Burtness, MD — Yale University School of Medicine

Maura L. Gillison, MD, PhD — The University of Texas MD Anderson Cancer Center

Kevin Harrington, PhD, FRCP, FRCR — The Institute of Cancer Research

Quynh-Thu Le, MD, FACR, FASTRO — Stanford University

Nancy Y. Lee, MD — Memorial Sloan Kettering Cancer Center

Rom Leidner, MD — Earle A. Chiles Research Institute, Providence Cancer Institute

Rebecca L. Lewis, CRNP — UPMC Hillman Cancer Center

Lisa Licitra, MD — Fondazione IRCCS Instituto Nazionale dei Tumori

Hisham Mehanna, PhD — Institute of Head and Neck Studies and Education

Loren K. Mell, MD — Dept. of Radiation Medicine and Applied Sciences, UC-San Diego

Adam Raben, MD — Christiana Care Health System

Andrew G. Sikora, MD, PhD — Baylor College of Medicine

Ravindra Uppaluri, MD, PhD — Dana-Farber Cancer Institute

Fernanda Whitworth — Co-founder of The Immunotherapy Foundation

Dan P. Zandberg, MD — UPMC Hillman Cancer Center